Compare Stocks

→ I’m officially sounding the alarm. (From Altimetry) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACUR Acura Pharmaceuticals	$0.00	$0.00	$0.00 ▼ $0.05	$186K	1.89	1,970 shs	163 shs
BNTC Benitec Biopharma	$6.74 -1.2%	$4.75	$1.86 ▼ $9.01	$17.46M	1.03	64,015 shs	13,836 shs
REXN Rexahn Pharmaceuticals		$2.06	$1.26 ▼ $4.26	$8.11M	0.98	162,968 shs	2,579 shs
ULUR ULURU		$0.00	$0.10 ▼ $0.79	$5.35M	-3.13	6,691 shs	N/A

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACUR Acura Pharmaceuticals	0.00%	0.00%	-20.00%	+154.55%	-94.40%
BNTC Benitec Biopharma	+42.08%	+9.47%	+34.52%	+139.30%	+74.42%
REXN Rexahn Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
ULUR ULURU	0.00%	0.00%	0.00%	0.00%	0.00%

I’m officially sounding the alarm. (Ad)

AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.

Just click here to watch my full uncensored interview.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACUR Acura Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	1.4723 of 5 stars	3.5	3.0	0.0	0.0	2.3	0.8	0.0
REXN Rexahn Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ULUR ULURU	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACUR Acura Pharmaceuticals	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	3.00	Buy	$10.00	48.37% Upside
REXN Rexahn Pharmaceuticals	N/A	N/A	N/A	N/A
ULUR ULURU	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest BNTC, ACUR, ULUR, and REXN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
2/15/2024	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$8.00 ➝ $10.00
1/24/2024	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$6.00 ➝ $8.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACUR Acura Pharmaceuticals	$1.56M	0.12	N/A	N/A	N/A	∞
BNTC Benitec Biopharma	$80K	218.21	N/A	N/A	$0.12 per share	56.17
REXN Rexahn Pharmaceuticals	N/A	N/A	N/A	N/A	$2.48 per share	N/A
ULUR ULURU	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACUR Acura Pharmaceuticals	-$880K	N/A	∞	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	-$19.56M	N/A	∞	N/A	N/A	-204.34%	-142.81%	5/20/2024 (Estimated)
REXN Rexahn Pharmaceuticals	-$8.64M	N/A	N/A	N/A	N/A	-72.60%	-55.68%	N/A
ULUR ULURU	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest BNTC, ACUR, ULUR, and REXN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/13/2024	Q2 2024	BNTC Benitec Biopharma	N/A	-$2.64	-$2.64	-$2.64	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACUR Acura Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
REXN Rexahn Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ULUR ULURU	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACUR Acura Pharmaceuticals	N/A	N/A	N/A
BNTC Benitec Biopharma	0.01	3.62	3.62
REXN Rexahn Pharmaceuticals	N/A	3.37	3.37
ULUR ULURU	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
ACUR Acura Pharmaceuticals	N/A
BNTC Benitec Biopharma	52.19%
REXN Rexahn Pharmaceuticals	7.49%
ULUR ULURU	N/A

Insider Ownership

Company	Insider Ownership
ACUR Acura Pharmaceuticals	20.20%
BNTC Benitec Biopharma	4.30%
REXN Rexahn Pharmaceuticals	1.10%
ULUR ULURU	1.10%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ACUR Acura Pharmaceuticals	9	66.35 million	52.95 million	Not Optionable
BNTC Benitec Biopharma	18	2.59 million	2.48 million	No Data
REXN Rexahn Pharmaceuticals	5	4.48 million	N/A	Optionable
ULUR ULURU	2	30.57 million	30.24 million	Not Optionable

BNTC, ACUR, ULUR, and REXN Headlines

Source	Headline
	The 11 Best Road Trips in the World outsideonline.com - April 18 at 4:50 AM
	Truth-telling risks inflaming community conflict: report afr.com - April 18 at 4:50 AM
	It’s political spending that feeds inflation, not Coles and Woolies afr.com - April 18 at 4:50 AM
	Truth, colonisation and Yoorrook: what is Victoria’s truth-telling inquiry and what will it achieve? theguardian.com - April 18 at 4:50 AM
	Better Homes & Gardens: April 19 tvtonight.com.au - April 17 at 5:32 PM
	LET THE GAMES BEGIN! REVERSE: 1999 FIRES OFF AUSTRALIA-THEMED VERSION 1.5 PHASE ONE UPDATE “REVIVAL! THE ULURU GAMES” TODAY capsulecomputers.com.au - April 16 at 9:30 PM
	Miguel Maestre teams up with Tourism NT and Luxury Escapes ntnews.com.au - April 15 at 8:22 PM
	‘My kids were heartbroken over Bluey’s biggest episode’ adelaidenow.com.au - April 14 at 2:03 PM
	The cost of marrying a British prince msn.com - April 14 at 2:03 PM
	Former soldier returns boomerang from nuclear test era to Maralinga's traditional owners msn.com - April 14 at 2:03 PM
	It’s time to tick Uluru off your family adventure bucket list ntnews.com.au - April 12 at 8:48 PM
	The Inland Sea: An Australian Odyssey avclub.com - April 12 at 8:55 AM
	There’s nothing to sea here: Cruise dining goes inland for some spectacular new experiences msn.com - April 12 at 12:54 AM
	Host a Screening of Living Black: Never Meant To Happen sbs.com.au - April 10 at 7:27 AM
	Qantas launches surprise 72-hour flight sale to more than 60 domestic destinations 7news.com.au - April 9 at 11:26 AM
	How to see the next 20 years of eclipses, including the eclipse of a lifetime msn.com - April 9 at 11:26 AM
	Ultra-rare, bizarre-looking blind mole photographed in Australia msn.com - April 9 at 11:26 AM
	I Lived Out of a Backpack for 2 Years on Working Holidays, and These Are the 17 Items I Relied on — From $8 msn.com - April 8 at 1:24 PM
	Next Governor-General’s deleted ‘Invasion Day’ tweets are simply incompatible with the values of Australia’s highest executive office skynews.com.au - April 7 at 8:57 PM
	Everything You Need To Know About Australia's Aircraft Boneyard In Alice Springs simpleflying.com - April 5 at 9:39 PM
	News live: heavy rain causes NSW train, bus delays as severe east coast weather continues; two Australians missing after Taiwan quake msn.com - April 5 at 1:18 AM
	‘Time to be fearless’: NT attorney general urges Australian leaders to pursue treaty after voice defeat theguardian.com - April 5 at 1:18 AM
	66 Of The World's Wonders You Can't Miss msn.com - April 4 at 8:18 PM
	Northern Territory tourism: Uluru’s Ayers Rock Resort nominated for two World Tourism Awards dailytelegraph.com.au - April 4 at 8:18 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acura Pharmaceuticals

OTCMKTS:ACUR

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.

Benitec Biopharma

NASDAQ:BNTC

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Rexahn Pharmaceuticals

NASDAQ:REXN

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

ULURU

OTCMKTS:ULUR

ULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. was founded in 1987 and is based in Addison, Texas.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial